Tag: iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials

RESEARCH TRIANGLE PARK, N.C., May 16, 2025–(BUSINESS WIRE)–IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic collaboration with the contract research organization arm of Sarah Cannon Research Institute, SCRI Development Innovations, aimed at transforming oncology trials for biopharma partners worldwide. By combining the capabilities of IQVIA and SCRI Development Innovations, this collaboration will enhance clinical trial processes, eliminate operational hurdles, accelerate data delivery and expedite the availability of cutting-edge therapies to patients.

The collaboration leverages IQVIA’s global reach and precision in managing one in five oncology trials in the United States, along with its ability to seamlessly integrate data, technology and analytics. These capabilities are combined with SCRI Development Innovations' community oncology expertise, and enhanced operational model, Accelero, which expedites trial activation and enhances recruitment for SCRI sites in the United States. Additionally, the Accelero model seamlessly integrates data from the electronic health record to the electronic data capture systems for U.S. clinical trial data collection. Together, these strengths offer sponsors a more effective pathway to operationalize the development of innovative treatments for patients.

"We are excited to announce our collaboration with SCRI Development Innovations," said Richard Staub, president of Research & Development Solutions at IQVIA. "This collaboration embodies our commitment to innovation, efficiency and delivering of superior outcomes for patients by bringing together the best of both organizations and eliminating the complexities often associated with multiple vendors. Together we will accelerate the development of new cancer therapies and improve outcomes for patients worldwide."

"We are enthusiastic about the impact we can make in transforming clinical trial delivery through our collaboration with IQVIA," said Dee Anna Smith, chief executive officer at Sarah Cannon Research Institute. "Through our accelerated operations model, Accelero, SCRI can alleviate the operational burden on research sites, enhance enrollment and expedite data delivery through our cutting-edge technology solutions. Additionally, we will leverage IQVIA’s global reach, expertise and capabilities in trial design and recruitment to provide a seamless global delivery model for our partners."

The collaboration between IQVIA and SCRI Development Innovations marks a significant step forward in transforming oncology trial delivery globally. Visit IQVIA at Booth 14103 or SCRI at Booth 27022 during the American Society of Clinical Oncology (ASCO) Annual Meeting May 30 to June 3 in Chicago, Ill., to learn more about this innovative partnership to advance cancer research and improve patient outcomes.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

About Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI’s research network brings together more than 1,300 physicians who are actively accruing patients to clinical trials at more than 250 locations in 24 states across the U.S. Visit scri.com to learn more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250516891083/en/

Contacts

Media Contacts

IQVIA:

Kerri Joseph, IQVIA Investor Relations ([email protected]) +1.973.541.3558

Alissa Maupin, IQVIA Media Relations ([email protected]) +1.919.923.6785

SCRI:

Becca Gelman, Marketing & Public Relations ([email protected])

In a groundbreaking move poised to reshape the landscape of oncology clinical trials, IQVIA, a trailblazer in global clinical research services, has joined forces with SCRI Development Innovations, the contract research organization branch of Sarah Cannon Research Institute (SCRI). This strategic collaboration aims to streamline and accelerate cancer research for biopharma partners worldwide, promising faster access to innovative therapies for patients battling cancer. Situated in the heart of Research Triangle Park, North Carolina, IQVIA brings a formidable reputation, managing one out of every five oncology trials across the United States with exceptional precision and integrating data, technology, and analytics seamlessly across the healthcare spectrum.

This alliance combines IQVIA’s vast global infrastructure and technological prowess with SCRI’s renowned community oncology expertise and its operational model, Accelero. The Accelero system is a game-changer, cutting activation times for clinical trials and optimizing patient recruitment across over 250 locations in the U.S. Its ability to integrate electronic health record (EHR) data directly into electronic data capture systems streamlines the otherwise complex data collection process, eliminating barriers that traditionally slow down clinical research progress. In essence, this partnership delivers a powerful synergy—IQVIA’s robust analytics and global reach converge with SCRI’s deep clinical insights and operational efficiency, crafting a smoother, faster pathway from research setup to groundbreaking therapy delivery.

Leaders from both organizations have expressed immense enthusiasm about the collaborative potential. Richard Staub, president of Research & Development Solutions at IQVIA, highlighted how merging the strengths of two industry leaders can eliminate the typical complications associated with managing multiple vendors in clinical trials. This focus on integration and efficiency is crucial as cancer therapies become increasingly complex, requiring adaptive trial designs and agile operational models. Dee Anna Smith, CEO of SCRI, echoed this optimism, emphasizing how the Accelero model reduces administrative burdens on research sites, boosts enrollment rates, and expedites data delivery using cutting-edge technology. This collaboration is not merely administrative—it’s a pivotal step toward enhancing patient outcomes through advanced, real-world oncology trial execution.

For those invested in the future of cancer treatment, the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting set in Chicago from May 30 to June 3 represents an unmissable opportunity. Both IQVIA and SCRI will be showcasing their innovative partnership at designated booths, offering insights into how their combined expertise accelerates cancer research and ultimately benefits patient care globally. Events like ASCO serve as critical convergence points where the latest advancements in oncology research and clinical trial innovation are shared, discussed, and propelled forward. The IQVIA-SCRI collaboration exemplifies the kind of concerted effort that fuels progress, marrying data-driven intelligence with hands-on clinical research capabilities on a global scale.

To appreciate the full scope of this partnership, it helps to understand the backgrounds of the key players involved. IQVIA is distinguished not only by its size—with an impressive workforce of about 88,000 professionals spanning healthcare, life sciences, data science, and technology—but also for its commitment to ethical AI use and regulatory compliance. Its proprietary IQVIA Connected Intelligence™ platform leverages healthcare-grade AI and advanced analytics to offer actionable insights, facilitating smarter decision-making in clinical development and commercialization. On the other side, SCRI’s legacy spans over three decades and includes more than 850 first-in-human trials, with a network of over 1,300 physicians across 24 states. This extensive clinical presence allows SCRI to execute trials at community sites that are closer to patients’ homes, thereby democratizing access to cutting-edge cancer therapies and boosting participant diversity in clinical trials. Together, IQVIA and SCRI bring complementary strengths that are set to revolutionize oncology research and shorten the timeline between scientific discovery and patient benefit.

#OncologyInnovation #ClinicalTrials #CancerResearch #IQVIA #SCRI #HealthcareAI #GlobalHealth